Get the free weekly contract digest
The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
New new contracts, summarized for you
No login, no app to check — it comes to you
See who's moving and how much in your market
KBI Biopharma Extends and Expands Commercial Contract with Leading Global Pharmaceutical Company
Contract Type
contract
DurhamManufacturingBiotechnologyDescription
KBI Biopharma, Inc. has extended and expanded its manufacturing contract with a leading global pharmaceutical company. The renewed contract extends through 2029 with a notable amendment that outlines a purchase commitment for two therapeutic products representing an incremental value of approximately $250 million through the end of the renewed term. Additionally, KBI completed a successful FDA regulatory inspection enabling the company’s North Carolina operations to begin providing a mammalian drug substance commercially to one of its key strategic customers, demonstrating KBI’s ability to act as a preferred partner for large volume commercial therapeutic manufacturing.